Literature DB >> 31060356

Tandem Decarboxylative Cyclization/Alkenylation Strategy for Total Syntheses of (+)-Longirabdiol, (-)-Longirabdolactone, and (-)-Effusin.

Jianpeng Zhang1, Zijian Li1, Junming Zhuo1,2, Yue Cui1, Ting Han1,3,2, Chao Li1,3,2.   

Abstract

Structurally complex and bioactive ent-kaurane diterpenoids have well-characterized biological functions and have drawn widespread attention from chemists for many decades. However, construction of highly oxidized forms of such diterpenoids still presents considerable challenges to synthetic chemists. Herein, we report the first total syntheses of C19 oxygenated spiro-lactone ent-kauranoids, including longirabdiol, longirabdolactone, and effusin. A concise synthesis of the common intermediate used for all three syntheses was enabled via three free-radical-based reactions: (1) a newly devised tandem decarboxylative cyclization/alkenylation sequence that forges the cis-19, 6-lactone concomitantly with vicinal alkenylation, (2) a Ni-catalyzed decarboxylative Giese reaction that constructs C10 quaternary center stereoselectively, and (3) a vinyl radical cyclization that generates a rigid bicyclo[3.2.1]octane. A series of late-stage oxidations from the common intermediate then provided each of the natural products in turn. Further biological evaluation of these synthetic natural products reveals broad anticancer activities.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31060356     DOI: 10.1021/jacs.9b03978

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  2 in total

Review 1.  Transition Metal-Mediated C-C Single Bond Cleavage: Making the Cut in Total Synthesis.

Authors:  Brian Wang; Melecio A Perea; Richmond Sarpong
Journal:  Angew Chem Int Ed Engl       Date:  2020-08-24       Impact factor: 15.336

2.  Evolution of a Strategy for the Enantioselective Synthesis of (-)-Cajanusine.

Authors:  Renyu Guo; Brittany P Witherspoon; M Kevin Brown
Journal:  J Am Chem Soc       Date:  2020-03-09       Impact factor: 15.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.